CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Black Diamond Reports Updated Phase 2 Silevertinib Data, FDA Registration Path

By Reuters News

Nov 10 (Reuters) - Black Diamond Therapeutics Inc BDTX.O:

  • BLACK DIAMOND THERAPEUTICS ANNOUNCES POSITIVE UPDATED SILEVERTINIB PHASE 2 RESULTS, FDA FEEDBACK SUPPORTING A CLEAR PATH TO POTENTIAL REGISTRATION IN 1L EGFR-NCM NSCLC, AND PROVIDES CORPORATE UPDATE

  • BLACK DIAMOND THERAPEUTICS - 60% ORR, 93% DCR, 15.0 MONTH MPFS IN ITT POPULATION

  • BLACK DIAMOND THERAPEUTICS - 86% CNS-ORR, 12.2 MONTH SYSTEMIC MPFS IN UNTREATED BRAIN METASTASES

  • BLACK DIAMOND THERAPEUTICS INC: ASSUMING A Q2 OF 2027 INITIATION, PRELIMINARY DATA ANTICIPATED IN 2028 FOR PHASE 3 TRIAL

Further company coverage: BDTX.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk